Member Comments are provided by individuals and reflect their personal opinions only. Under NO circumstances should you act on any advice or opinion posted in this forum. ALWAYS check with your personal physician before taking any action regarding your health! MedHelp International and our partners, sponsors and affiliates have no obligation to monitor any comments posted on this site, or the content and/or accuracy of such exchanges. MedHelp International does not endorse the views of any user.
Hi,
Alopecia areata is also called as Auto-immune alopecia. It is defined as recurrent, non-scarring type of hair loss, most likely caused by autoimmune processes. The pathogenesis is probably T-cell mediated; occurs in genetically predisposed individuals. Clinical manifestation includes non-scarring, non-inflammatory, patterned alopecia; one or many round-to-oval bald patches; exclamation point hairs (i.e. hairs tapered near proximal end) often present; most commonly occurring in the scalp, but possible in any hair-bearing area.
Therapy consists of localized disease like triamcinolone 2–4 mg/ml intra-lesional; high potency topical corticosteroids.
References: Madani S, Shapiro J (2000) Alopecia areata update. Journal of the American Academy of Dermatology 42(4):549–566.
Alopecia areata is also called as Auto-immune alopecia. It is defined as recurrent, non-scarring type of hair loss, most likely caused by autoimmune processes. The pathogenesis is probably T-cell mediated; occurs in genetically predisposed individuals. Clinical manifestation includes non-scarring, non-inflammatory, patterned alopecia; one or many round-to-oval bald patches; exclamation point hairs (i.e. hairs tapered near proximal end) often present; most commonly occurring in the scalp, but possible in any hair-bearing area.
Therapy consists of localized disease like triamcinolone 2–4 mg/ml intra-lesional; high potency topical corticosteroids.
References: Madani S, Shapiro J (2000) Alopecia areata update. Journal of the American Academy of Dermatology 42(4):549–566.